

1AP7 Rec'd PCT/PTO 12 APR 2006

PCT



PATENT

Attorney Docket 056291-5213

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: **Jon Owen CURWEN *et al.***)

Application No. 10/555,389)

Group Art Unit: *Unassigned*

Filed: November 3, 2005)

Examiner: *Unassigned*

For: **Therapeutic Agents Comprising an
Anti-Angiogenic Agent in Combination
with an Src-Inhibitor and Their
Therapeutic Use**)

Dated: April 12, 2006

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant petitions the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicant does not believe a fee is due for filing this Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence for consideration by making appropriate notations on the attached form.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts

and law regarding the appropriate status of such document.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or to credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: April 12, 2006
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

(Use several sheets if necessary)

APR 12 2006
PATENT & TRADEMARK OFFICE

Group Art Unit: Unassigned

[illegible]

		Document No.	Date	Country	Class	Sub-Class	Translation
	1.	WO 97/22596	June 26, 1997	WIPO			
	2.	WO 98/13354	April 2, 1998	WIPO			
	3.	WO 00/21955	April 20, 2000	WIPO			
	4.	WO 01/32651	May 10, 2001	WIPO			
	5.	WO 01/94341	December 13, 2001	WIPO			
	6.	WO 02/085895	October 31, 2002	WIPO			
	7.	WO 02/092577	November 21 2002	WIPO			
	8.	WO 02/092578	November 21, 2002	WIPO			
	9.	WO 02/16352	February 28, 2002	WIPO			
	10.	WO 03/064413	August 7, 2003	WIPO			
	11.	WO 2004/087120	October 14, 2004	WIPO			
	12.	WO 2005/014582	February 17, 2005	WIPO			

[illegible]

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.